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ABSTRACT
An increasing number of genes encoding PLP-dependent transcription regulators and
MocR/GabR type regulators have been identified in various bacterial genomes. However, only a
handful of them, including MocR, PdxR, and GabR have been studied experimentally. They
control different aspects of the bacterial metabolism. Only GabR has a reported crystallographic
structure. MocR/GabR regulators possess a chimeric structure consisting of a winged helix-turnhelix (wHTH) DNA binding domain and an aminotransferase-like regulatory domain, which can
bind PLP as an effector in transcription regulation. Such a chimeric construct presents a
compelling case in molecular evolution. The regulation domains of all MocR/GabR type
regulators loss their catalytic capacity during evolution and function as means of effector
recognition and transcription regulation. A MocR/GabR homolog in Klebsiella pneumoniae has
recently been studied; this homolog is currently named Duf161R (YczR) since it is putatively
believed to control a gene encoding a membrane protein annotated as “domain of unknown
function 161”.
The three-dimensional crystal structure of the regulatory domain of YczR have been
determined to a resolution of 1.79 Å. Our crystallographic studies hav revealed the structure of a
truncated regulation domain with PLP bound, and our spectroscopic studies have collected
evidence to support at least partial transaminase-like catalytic activity of the regulatory domain.
Together with DNA binding studies, we provide data on a new case of MocR regulation and its
currently unconfirmed biological function, which is likely augmenting pathogenesis via
xix

facilitating taurine trafficking in K. pneumoniae.
Together with DNA binding studies, we provide data on a new case of MocR regulation and
its currently unconfirmed biological function, which is likely augmenting pathogenesis via
facilitating taurine trafficking in K. pneumoniae.
During my Ph.D. program, I also worked on several other protein projects. I have included
chapter two for the PTP1B project. Protein tyrosine phosphatase 1B (PTP1B) is an enzyme
shown to play an essential role in insulin regulation. PTP1B is a critical negative regulator of
insulin and leptin signaling pathways by removing phosphate groups (PO43-) from insulin
receptor and other post-receptor substrates. Previous studies have identified transition metal
compounds that exhibit insulin-mimetic effects. A plausible explanation is that vanadiumcontaining compounds and zinc-containing compounds inhibit PTP1B activity, which allows the
required phosphorylation reaction to proceed normally. One specifically modified vanadiumcontaining compound has been synthesized. This research has determined the three-dimensional
crystal structure of PTP1B and VO(acac)2 complex to a resolution of 2.2 Å. Furthermore, the
kinetic data suggest a mixed inhibition because of the aqueous study of the vanadium complex.
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CHAPTER ONE
YCZR, A NEW CASE OF PLP-DEPENDENT MOCR/GABR TYPE TRANSCRIPTION
REGULATOR IN KLEBSIELLA PNEUMONIAE
Research Aims: YczR may be Potential Anti-Virulence Target for Klebsiella pneumoniae
Klebsiella pneumoniae is a Gram-negative, facultatively anaerobic bacterium[1-3]. It can
reside in the human flora of the mouth, skin, and intestines[2, 4, 5]. Once aspirated to the lungs,
specifically to the alveoli, it can cause hemoptysis and destructive changes to human and animal
lungs[3, 6]. It also can lead to a range of different illnesses, such as wound infections, urinary tract
infections (UTI), bloodstream infections, meningitis, surgical site infections, and pneumonia[7-9].
K. pneumoniae is a multi-drug resistant bacterium and consumes taurine as part of the
pathogenesis infecting humans.
Klebsiella infections commonly occur among patients who take long courses of certain
antibiotics. Patients who have intravenous catheters or are on a ventilator are are also at a higher
risk of Klebsiella infections[10-14].
According to the Centers for Disease Control and Prevention (CDC) Healthcare-associated
Infections (HAI) reports, doctors use several powerful antibiotics, such as polymyxins,
fosfomycin, and aminoglycosides in conjunction to treat Klebsiella infections. However,
Klebsiella is increasingly becoming resistant to antibiotics[4]. The highly antibiotic-resistant
“superbug” bacteria belong to the carbapenem-resistant Enterobacteriaceae (CRE) family[5, 15].
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Carbapenem-resistant K. pneumoniae (CR-Kp) is the most common type of CRE.
According to CDC guidelines, CR-Kp is responsible for approximately 7,900 infections and 520
deaths each year[16, 17]. Some strains of K. pneumoniae can produce Klebsiella pneumoniae
carbapenemases (KPC) to render the antibiotics ineffective. KPC-producing bacteria are resistant
to most classes of known antibiotics, including carbapenems, which are considered as a drug of
last resort (DoLR) against antibiotic-resistant Gram-negative infections[6, 16]. Drug resistance and
diminished effect of medication on bacteria and other infectious diseases are becoming one of
the most significant health issues of the 21st century. To combat this problem, novel
antimicrobial targets need to be identified[2].
Gene Transcription and Transcription Factors
Gene transcription is fundamentally important for metabolism and normal physiological
activities at the first step of gene expression. During transcription, RNA polymerase uses a
particular segment of genomic DNA as a template to synthesize a single-stranded
complementary mRNA primary transcript[18]. Therefore, transcription is a highly regulated
process.
Bacteria adapt to environmental changes by carrying out highly sophisticated responses via
transcription regulation. Transcription factors (TFs) control transcription regulation by binding to
specific DNA sequences and leading to either activation or repression of certain genes. TFs
recognition of specific DNA binding sites is essential for mediating gene expression and
repression in different cellular contexts.
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TFs employ a variety of mechanisms to recognize target nucleotide sequences such as
hydrophobic contacts and hydrogen bonds between DNA bases and amino acid side chains. They
can bind to the specific promoter or regulatory regions of DNA by a variety of unique domains
or motifs such as zinc fingers, leucine zippers, helix-turn-helix (HTH) domains, sheet DNAbinding proteins, and transcription activator-like effector (TALE) domains. TFs can also
recognize the local three-dimensional (3D) shape of the target DNA sequence at the proteinbinding site, including sequence dependent narrowing of the DNA minor groove.
TF’s play several critical biological roles in bacteria, such as basal transcription regulation,
cell cycle control, intercellular signal response, pathogenesis, environmental response, and
differential enhancement of transcription[19, 20]. Therefore, TFs are potential antimicrobial targets.
Based on biophysical, molecular, computational, and X-ray crystallography studies over the
past decade, scientists have located numerous TFs binding sites, by deducing from aligning a set
of DNA sequence that is experimentally known[21]. However, understanding the TFs binding
mechanisms has proven to be a challenge, especially concerning mechanisms details. The
primary difficulty is in bridging the gap between genomic-scale overview and molecular
description at molecular level.
GntR family and the subfamily classification
The GntR family is a widespread and large group of bacterial TFs. It was named GntR after
Haydon and Guest had identified and described the first GntR family member the Bacillus
subtilis gluconate operon repressor in 1991[22]. The database of protein families (Pfam) currently
stores approximately 8,561 regulatory proteins of the GntR family (Pfam family: GntR,
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PF00392), which spread out among 764 bacteria taxa[23]. In the protein data bank (PDB) the
metabolite-response GntR family has approximately 106 protein structures been solved.
GntR family TFs often bind to DNA sequences adjacent to the genes which they control.
There are many cases in which TFs bind as effectors. In some instances, GntR TFs are also not
located close to the gene it regulates. One of the well-studied examples is FadR, the
multifunctional regulator of fatty acid metabolism in E. coli[24].
The GntR family TFs can regulate various biological processes including metabolism of
fatty acid, amino acids, utilization of sugars and other carbon sources[22, 25]. Among all bacterial
transcription regulators, the GntR superfamily proteins are structurally featured by N-terminal
wHTH DNA-binding domains along with a heterogeneous C-terminal regulatory, effectorbinding/oligomerization (Eb/O) domain, which provides a basis for the constituent subfamilies
classification.
While the DNA binding domains in this superfamily share a significant level of similarity,
as all exhibit the wHTH domain with the canonical HTH motif followed by a beta-turn-beta
wing hairpin, the C-terminal regulatory ligand binding domains vary significantly. The
characteristics of the C-terminal domains provide a basis for the current classification of the
GntR subfamilies: HutC, MocR, YtrA, AraR, DevA, PlmA[26-28] (Figure 1) and, the largest
subfamily, FadR[25, 27, 29].
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Figure 1. Classification of Mycobacterium smegmatis GntR regulators including representatives
of all subfamily regulators from different bacterial genomes with 1000 bootstrap replicates. All
the GntR regulators are clustered into six subfamilies. FadR subfamily is branched again into
two groups (VanR and FadR)[26].
FadR subfamily is the largest GntR subfamily of all GntR-like regulators. The FadR family
primarily functions in regulating the expression of enzymes responsible for oxidizing substrates
related to amino acids, or substrates that emerge from the central metabolism. FadR is named
after the best-characterized GntR repressor, the acyl-CoA responsive regulator that regulates
fatty acid metabolism[30, 31]. The crystal structure for FadR of Thermotoga maritima transcription
regulator TM0439 is shown in Figure 2 (PDB ID: 3FMS)[32].
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Figure 2. Quaternary structure of Thermotoga maritima GntR/ FadR bacterial transcription
regulator TM0439 (PDB: 3FMS)[32].
The FadR C-terminal domain characteristically contains 150-160 amino acids, which form a
six to seven α-helical bundle that binds carboxylic acids and other small organic ligands. A
unique feature of this family is a kink in helix four which is involved in dimerization.

Figure 3. Quaternary structure of Bacillus subtilis GntR/ HutC bacterial transcription regulator
YvoA(PDB: 2WV0)[33].
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HutC is the second major GntR subfamily accounts of all GntR-family transcription
regulators[31]. The HutC C-terminal domain is approximately 170 amino acids in length and
consists of α-helices and β-sheets [25]. Although the HutC C-terminal domain lacks enzymatic
activity, it shares a similar fold with chorismate from E.coli; it can bind effectors such as
histidine, fatty acids, and sugars. This subfamily derives its name from HutC regulator in
Pseudomonas putida which is involved in regulating histidine utilizing genes[31]. Capable of
binding to a wide range of effector ligands, HutC regulators are involved in a variety of
processes such as conjugative plasmid transfer, sensing of nutritional status in the environment,
and antibiotic production[30, 31]. The X-ray structure of the GntR/HutC bacterial transcription
regulator YvoA is shown (Figure 3; PDB ID: 2WV0)[33].

Figure 4. Quaternary structure of Corynebacterium glutamicum GntR/ YtrA bacterial
transcription regulator CGL2947 (PDB: 2DU9).
Most members of the YtrA subfamily form operons with ATP-biding cassette transport
systems[25]. This subfamily contains a characteristically short 50 amino acid two helices Cterminal domain. The short domain suggests that effector ligand binding is not likely without
dimerization. Dimerization is commonplace as many GntR-like palindromic repeats have been
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identified upstream of regulated operons[30]. Furthermore, the abundance of hydrophobic,
aromatic, negatively charged, and positively charged residues at the end of the domain suggests
that dimerization most likely occurs through side-chain-side-chain interactions and salt
bridges[25]. This hypothesis was verified via the crystal structure of CGL2947 from
Corynebacterium glutamicum (Figure 4), which showed a homodimer assembly[34].
MocR/GabR
MocR/GabR, the last of the major families, is characterized by a large Cterminal/oligomerization domain with an average of length of 350 amino acids (Figure 5). This
domain is homologous to type I aminotransferases, which catalyze the formation of α-keto acids
from amino acids using PLP as a cofactor[25]. GabR from B. subtilis, the representative member
of this family, regulates γ-aminobutyric acid (GABA) metabolism. GABA is an important carbon
and nitrogen source. In many bacteria, B. subtilis GABA could act as the sole nitrogen source[35].
GabR regulates the gabTD pathway in a PLP and GABA dependent manner (Figure 6). In the
presence of PLP, GabR will repress its transcription, upon binding to GABA, GabR upregulates
the gabTD pathway promoting GABA metabolism and glutamate biosynthesis. The gabTD
pathway consists of two genes, which allow for the use of intracellular GABA to generate
succinate and glutamate[35].
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Figure 5. Quaternary structure of Bacillus subtilis GntR/ GabR bacterial transcription regulator
GabR (PDB: 4N0B)[36].

Figure 6. Schematic of GabR binding sites at the gabTD and gabR promoters. A schematic of the
gabR and gabTD gene location is shown here. The arrows indicate the transcription directions
and starting sites for the gabTD and gabR genes. Within the gabR-gabT regulatory region, the
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two direct repeats (ATACCA) are indicated, and the 47-bp GabR binding site (-63 to -17) is
shown in detail.
The two genes, gabT and gabD, encode for the enzymes GABA aminotransferase (GABAAT) and succinic semialdehyde dehydrogenase (SSADH), respectively. GABA-AT catalyzes the
ping-pong transamination using GABA as an amino group donor, PLP as a coenzyme, and αketoglutarate as an amino group acceptor. In the first half reaction, GABA donates its amino
group to PLP forming pyridoxamine 5’-phosphate (PMP) and releases succinic semialdehyde. In
the second half reaction, PMP donates its amino group to α-ketoglutarate forming glutamate and
regenerating PLP. Downstream, the GabD succinate semialdehyde dehydrogenase will convert
succinic semialdehyde to succinate[37].
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PLP Pyridoxal phosphate
Pyridoxal 5'-Phosphate (PLP) is the active biological form of vitamin B6, which exists in
the form of six interconvertible vitamers: pyridoxine, pyridoxamine, pyridoxal and their 5’phosphorylated forms[38-40]. PLP acts as a coenzyme in a variety of enzymatic reactions in all
organisms, such as deamination, decarboxylation, racemization reactions of amino acids and in
vast majority of transamination reactions[41].
The Enzyme Commission (EC) has identified more than 145 PLP-dependent activities
which corresponding to about 4% of all classified activities[42]. Almost 1.5% of genes generally
encode PLP-dependent enzymes in the free-living prokaryotic genomes[42]. The most common
PLP-dependent enzymes are phosphorylases, aminotransferases, decarboxylases, glycogen
amino acid racemases, and enzymes catalyzing β- or γ-elimination or replacement. The utility of
PLP lies in its ability to stabilize carbanionic reaction intermediates by acting as an electrophilic
catalyst after covalently binding to substrates. PLP is also involved in stress responses, especially
to oxidative stress, which can quench reactive oxygen species[43]. The dysregulation of PLP
metabolism can cause various physiological deficiencies, such as reduced glucan production,
lowered stress tolerance, growth inhibition and biofilm formation[43].
Some PLP-dependent enzymes generate enamine/imine intermediates that can inactivate
other enzymes by covalent binding to their active site, whereas the RidA-family proteins quench
these reactive intermediates to prevent metabolic damage[44].
The PLP aldehyde group can form a Schiff base linkage (internal aldimine) with the εamino group of the specific lysine group of the aminotransferase enzyme. In the
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transaldimination, the amino acid substrate α-amino group displaces the ε-amino group of the
active-site lysine. And then, the external aldimine can lose a proton, an amino acid side chain or
carbon dioxide to form a quinoid intermediate, which can act as a nucleophile in several reaction
pathways[38, 45, 46].
Domain of unknown function
Domains of unknown function (DUF) are a large set of uncharacterized protein families that
are found in the Pfam database that has no characterized function[47, 48]. More than 20% of all
protein domains in the protein family’s database were annotated as DUFs in 2013[49]. The
number of DUFs is substantially increased with the rapidly accumulating genome sequencing
data[47]. These genes have been collectively given in the Protein family’s database the prefix
DUF followed by a number. Some DUFs are highly conserved, indicating an important role in
biology. However, the biological function of many DUFs often remains unknown because such
proteins are not essential[48, 49]. Structural genomics program has attempted to understand the
function of DUFs through structure determination. The structure of more than 250 DUF families
proteins have been solved[49]. These protein families have been collected together in the Pfam
database using the prefix DUF followed by a number. There are over 3,000 DUF families in the
Pfam database representing over 20% of known families[49].
DUF161 is an uncharacterized hypothetical membrane protein, belonging to YitT family.
This entry describes proteins with a trans-membrane domain. The functions of this family are
unclear. The PDB entries over 50,000 protein structures, but less than 1% of them are membrane
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proteins. Membrane proteins have proven to be challenging to study owing to their flexibility,
partially hydrophobic surfaces, and lack of stability[50].
MocR/YczE
Generally, YczE and YitT family protein have been annotated as “membrane proteins
containing the DUF161 domain”. YczR, in K. pneumoniae, is the transcriptional regulator of
DUF161. The crystal structure of YczR would provide information to speculate on the function
of DUF161.
The TF of yczE genes, named YczR, predicted to constitute a MocR subfamily. Bacterial
YczE family proteins are predicted to be unknown function membrane proteins which prosessing
five trans-membrane helices. Based on the Conserved Domain Database (CDD), code COG2364
belongs to the YczE family. Corresponding to the Pfam database (code: PF02588), InterPro
databank (code IPR003740), and CDD (code COG1284), YczR and YitT family shared the
presence of DUF161 domains. Based on the annotations report of the databanks, YczE and YitT
family do not have apparent differences[51]. Possibly, they may be distinguished by the absence
of the C-terminal DUF2179 domain in YczE, corresponding to the Protein Data Bank (PDB)
structure PDB: 3HLU, present in the members of the YitT family[51, 52].
YczR, in K. pneumoniae, is the transcriptional activator of YczE, which belongs to the
transcriptional regulator MocR family. It is supposed to regulate the expression of the yczE
genes. MocR regulators are a subfamily belonging to the class of GntR regulators characterized
by the presence of a short N-terminal wHTH DNA-binding domain and a long C-terminal
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regulatory domain. The C-terminal domains belong to the superfamily of the PLP enzymes of the
fold type I[53].
Two members of the MocR/GntR family have been characterized in detail, GabR, and PdxR.
GabR positively regulates the expression of the gabTD operon, which is responsible for the
utilization of gamma-Aminobutyric acid[36, 54]. PdxR regulates the expression of the pdxST
genes[55].
Obtaining the structure of YczR will help us in speculating the function of YczE. In our
current research, we have solved the K. pneumoniae YczR regulator domain crystal structure and
apo-YczR crystal structure. Based on the structure, we speculate that YczR might have a half
alanine-glyoxylate transaminase activity. Based on this speculation, we designed the UVabsorption spectroscopic measurements, end-point enzymatic assays, and fluorescence
spectroscopy. Alanine-glyoxylate aminotransferase catalyzes the transfer of the L-alanine to
glyoxylate, forming glycine and pyruvate. In the first half-transamination reaction, L-alanine
reacts with the pyridoxal form of the enzyme to yield the pyruvate and the pyridoxamine form of
the enzyme[56-60]. We also used size exclusion chromatography with multi-angle light scattering
(SEC-MALS), small-angle x-ray scattering (SAXS), mass spectrometry, and transmission
electron microscopy (TEM) methods to gain an in-depth understanding of the characteristics of
YczR and valuable clues for the function of YczE. We used fluorescence polarization assay to
determine the YczR binding DNA sequence. Fluorescence polarization assays are suitable for the
analysis of binding between the small fluorescence-labeled DNA fragment and its significantly
larger binding protein[61].

CHAPTER TWO
CRYSTAL STRUCTURE OF KLEBSIELLA PNEUMONIAE YCZR, THE
TRANSCRIPTIONAL REGULATOR OF THE DOMAIN OF UNKNOWN FUNCTION 161
(DUF161)
Research Significance
YczR is a member of the understudied MocR/GabR subfamily of the GntR family of
transcription regulators. A Typical GntR/MocR subfamily protein contains a large C-terminal
putative type I aminotransferase domain and a small N terminal wHTH DNA binding domain [25,
35]

.
In the present study, we report two K. pneumoniae YczR regulator domain crystal

structures: a 1.79 Å structure of YczR with PLP bound and the 2.0 Å apo structure of YczR
regulator without PLP. We also used size exclusion chromatography with multi-angle light
scattering (SEC-MALS), small-angle x-ray scattering (SAXS), and mass spectrometry methods
to gain an in-depth understanding of the biological assembly of YczR. To our best knowledge,
these crystal structures of YczR were described for the first time.
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YczR is a Homodimer
The YczR protein of K. pneumoniae has a predicted size of 475 amino acids and a
theoretical molecular mass of 52.25 kDa. YczR was eluted as one major peak on a Superdex 200
gel-filtration column during protein purification, with an apparent molecular weight of a dimer
(108 kDa), indicating a dimer of YczR in solution (Figure 7).

Figure 1. The gel filtration purification profile of YczR. The YczR major peak (fractions B9B12) on Superdex 200 16/60 corresponds to an apparent molecular weight of a dimer.
YczR crystallizes as a homodimer with the two AT-fold domains organized in a head-tohead domain arrangement (Figure 8 & 9). As seen in all type I aminotransferases[62, 63], this
interface of YzcR contains two PLP-binding pockets bound by one molecule of PLP in each
pocket. The large dimer interface between the two AT-domains further suggests that any such
domain movements by the wHTH domain do not require restructuring of the AT-AT interface.
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Figure 2. Quaternary structure of K. pneumoniae YczR regulator domain. YczR should be a
head-to-tail domain-swap homodimer. The AT-fold domains are shown in red and blue. An
orthogonal view of the structure is shown in Figure 9.
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Figure 3. Quaternary structure of K. pneumoniae YczR regulator domain. The structure is rotated
90° counterclockwise along the y axis relative to Figure 8.
The structure of YczR was solved by molecular replacement and refined to 1.79 Å
resolutions. The final model contains 385 residues, yielding a crystallographic R-value of
19.11% and an R-free value of 22.84% with near ideal chemical geometry. Two molecules in an
asymmetric unit formed a homodimer. Two active sites at the interface of the subunits are shown
with PLP in element-colored sticks.
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PLP is Bound in the C-terminal AT-Fold Domain
Based on the amino sequence, the YczR should have a short N-terminal wHTH DNA-bing
domain and a long C-terminal PLP-binding putative aminotransferase domain. However, the Nterminal wHTH DNA-binding domains have not been found in YczR crystal structure. We
speculated that we lost the DNA-binding domain when we purified the protein or during
crystallization. The regulation domain structure still provides insights into YczR funcations.
PLP is bound to the C-terminal regulator Domain (Figure 10). The PLP binding pocket also
corresponds to the cofactor binding sites in the related enzymes and therefore defines the active
site of YczR.

Figure 4. Quaternary structure of YczR AT-fold domain monomer. PLP is bound in the AT-fold
domain of YczR. Side chains of the key residues that interact with PLP are shown in stick
representation. The secondary structure elements are shown in cartoon form.
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Figure 5. Structure of YczR regulator domainPLP-binding pocket. The residues with 4 and 5 Å
from K311-PLP were labeled. The PLP and surrounding side chains are shown as sticks. Carbon
atoms are shown in gray, oxygen atoms in red, and nitrogen atoms in blue.
One molecule of PLP forms an internal aldimine with the ω-amino group of K311 per YczR
monomer. As with other types I aminotransferases[62, 63], the YczR AT-fold domain has two
subdomains, the small subdomain that typically interacts with the α- carboxylate group of the
substrate and the large subdomain containing the invariant lysine (K311) that forms the Schiff
base with PLP. The interaction between the ASP278 and pyridine nitrogen of PLP probably
could protonate the pyridine nitrogen. Although the effectors were unknown, those structure
features remain.
In amino transferase reaction, the principal function of PLP is to stabilize the negative
charge generated at external aldimine between PLP and the amino acid substrate or the Cα atom

21
of the transition state by delocalizing the negative charge through the π-electron system of the
cofactor[36].
The YczR AT-fold domain residues that interact with PLP are shown (Figure. 11): The C4A
atom of PLP is covalently attached to the LYS311 through the formation of an internal Schiff
base. The PLP-pyridine ring stacked with residues Tyr-201 by formed pi-pi hydrophobic
interactions. The C2A atom of PLP exhibits hydrophobic interaction with a Met-245 side chain.
The phosphate group of PLP forms hydrogen bonds and salt bridges with Ser-308, Ala-176, and
Arg-318. The side chains of Thr-280, Asp-278 and Asn-250 are hydrogen bonded to N-1 and O3 of the PLP-pyridoxal, respectively. The phosphate moiety of the PLP formed hydrogen bonds
with the peptide side chains of residues Arg-318 and Ala-176. This conformation allows
hydrogen bond with the Lys-311 and could also interact with the amino group from the
pyridoxamine intermediate during the enzymatic reaction.
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Figure 6. PLP binding pockets. (A) A surface-coated YczR(blue) is shown with the PLP product
as sticks (carbons colored gray, oxygen colored red and nitrogen colored blue). The PLP is
buried below the surface. (B) A rotated, cut-away view of panel A, showing a defined pocket for
binding the PLP, while the opened ring is pointing toward the solvent.
Compared with the structure of GabR, PLP binding pocket in the YczR AT-fold domain has
bigger size of the opening (Figure 12). PLP is buried below the surface of the protein. Once the
internal aldimine between PLP and the K311 broken, the molecular PLP or PMP would be
released from binding pocket easily.
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Figure 7. Comparison of the structure of K. pneumoniae YczR with B. subtilis GabR (PDB ID:
4N0B). An orthogonal view of the GabR structure is shown in pink. An orthogonal view of the
YczR AT-fold domain is shown in blue.
The crystal structures of K. pneumoniae YczR and B. subtilis GabR (PDB ID: 4NOB) were
compared to analyze the difference in the overall structure (Figure 13). The YczR AT domain
size was very similar to that B. subtilis GabR reported. GabR has a long linker connecting Cterminal AT-fold domain to the N-terminal winged-helix domain. YczR lost the N-terminal
DNA binding domain in the crystal structure.
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Structure of Apo-YczR
We also attempted to get YczR with L-alanine co-crystal. In the resulting crystal structure,
PLP is no longer bound in the PLP-binding pocket. The PLP-binding site of the crystal structure
of apo-YczR is shown (Figure 14). The purified YczR protein is pale yellow, which suggested
that endogenous PLP from E. coli bound to YczR after purification. After co-crystallization of
YczR and L-alanine, the apo-YczR crystal is clear in color. This result indicated that Schiff base
between the invariant lysine (Lys-311) and PLP had been broken.

Figure 8. Quaternary structure of apo-YczR AT-fold domain. PLP is no longer bound in the
PLP-binding pocket. The secondary structure elements are shown in cartoon form.
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One small molecular binds with Ser-308. Apo-YczR crystal crystallization solution
contained 8% (V/V) Tacsimate, pH 6.0. Tacsimate is a unique crystallization reagent, which is
composed of a mixture of titrated organic acid salts, developed exclusively by Hampton
Research. Tacsimate contains malonic acid, ammonium citrate tribasic, succinic acid, DL-malic
acid, sodium acetate trihydrate, sodium formate, and ammonium tartrate dibasic. We cannot
jump to the conclusion that L-alanine replaced PLP. We still need to get the same structure result
from crystallization solution without Tacsimate.
The crystal structures of YczR-PLP and apo-YczR were compared to analyze the difference
in the overall structure (Figure 15). The obtained apo-YczR structure with no PLP bound has a
similar overall conformation when compared to YczR-PLP. The overall similarity suggests that
the apo-YczR AT-fold domain maintains the overall structural integrity even when PLP is no
longer bound.
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Figure 9. Comparison of the YczR-PLP and apo-YczR AT-domain. The YczR-PLP structure is
shown in orange red and in cyan for the apo-YczR structure.
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Table 1. Crystallographic data collection and refinement statistics for YczR and Apo-YczR
YczR

Apo-YczR

C222

C222

Data Processing
Space group
Cell dimension
α, β, γ (deg)
a, b, c (Å)
Resolution (Å)
Resolution at I/σ (I) =2
R (%)
I/σ (I)
CC ½
Completeness (%)
Multiplicity
No. Reflections
No. Unique Reflections
pim

a

b

1

123.482, 181.139, 108.567
90.0, 90.0, 90.0
1.82
1.85
2.9(38)
25.5(13.4)
0.757
99.4(91.7)

1

123.24, 180.005, 106.006
90.0, 90.0, 90.0
2.46
2.73
5.5(60)
13.2(10.9)
0.575
99.7(97.3)

110262
45635

Refinement
R /R (%)
No. of Atoms
protein
ligand
water
B factors (Å )
protein
ligand
RMSD
bond lengths (Å)
bond angles (deg)
Ramachandran plot (%)
most favored
allowed
outliers
work

c

free

d

17.64/21.13

20.8/28.96

8448
60
650

8001
30
152

30.0

48.912

0.02
2.07

0.01
1.67

2

e

a

Precision-indicating merging R
Pearson correlation coefficient of two “half”data sets
c
Rwork = Σ|Fobs − Fcalc|/ΣFobs
d
Five percent of the reflection data were selected at random as a test set, and only these data were used to calculate Rfree
e
Root-mean square deviation
h
Not applicable
b
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To determine at which step the DNA-binding domain of YczR was lost, mass spectrometry
is used to determine the molecular weight of YczR monomer (Figure 16) immediately after
FPLC purification. YczR monomer has 474 amino acids, which theoretically molecular weight is
52,112 Da. In the absence of PLP, the Mass Spectrometry plot shows a predominant peak at
52933 Da, which suggesting a full-length of YczR in solution after FPLC purification. We
speculate that protein lost N-terminal winged-helix domain during crystallization step.

Figure 10. Mass spectrometry data of YczR-PLP monomer.
To determine if YczR is a dimer in solution, SEC-MALS was used to assay YczR oligomers
(Figure 17). Purified YczR was eluted from the size-exclusion column as a single peak detected
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by Abs280. The molecular weight of 121 ± 5 kDa for this peak is determined by light scattering,
which matches the mass calculated for the dimer from the expected sequence (52112 Da × 2 =
104224 Da). YczR came out to be pretty homogeneous with small levels of aggregates that
eluted right before the main peak and hence, may lead to an overestimation of the molecular
weight of the main peak. Therefore, speculate YczR even at very low protein concentration still
forms a dimer that appears a little bigger in solution. SEC-MALS data do not show YczR
tetramers or higher oligomers exist in solution; however, further YczR oligomerization may still
occur when the protein binds to DNA.

Figure 11. Molecular weight determinations of YczR in solution. SEC-MALS profiles are shown
for YczR. The absorbance at 280 nm is shown as a black line, and the calculated molecular
weight for protein in the eluent at a particular time is shown in color, as noted. YczR (molecular
weight in red) gives a single peak with a molecular weight of 121 ± 5 kDa.
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Figure 12. The overall comparison of K. pneumoniae YczR and B. subtilis GabR (PDB ID:
4N0B) SAXS models.
Both YczR and GabR belong the MocR/GabR subfamily of GntR family of transcription
regulator[36]. The SAXS model of K. pneumoniae YczR and B. subtilis GabR (PDB ID: 4NOB)
(Figure 18) were compared to analyze the difference in overall size. Based on the SAXS model
comparison result, the volume of YczR dimmer in solution was bigger than GabR. The result
suggested that YczR was containing the much extensional DNA-binding domain. The whole
structure of YczR should be more extensional.

CHAPTER THREE
YCZR REGULATION DOMAIN CATALYZES A REVERSIBLE HALF-TRANSAMINASE
REACTION INSTEAD OF BEING A NON-ENZYMATIC REGULATOR LIKE GABR
The crystal structure of YczR showed that PLP was bound to the regulator domain reacted
with the lysine (Lys-311) to form a stable internal aldimine, which likely controls the
transcription from the yczE promoter in K. pneumoniae.
Alanine-glyoxylate aminotransferase catalyzes the transfer of the amine of L-alanine to
glyoxylate, forming glycine and pyruvate. In the first half-transamination reaction, L-alanine
reacts with the pyridoxal form (PLP) of the enzyme to yield the pyruvate and the pyridoxamine
form (PMP) of the enzyme[56-60]. Based on comparison of the crystal structure of YczR with
alanine-glyoxylate transaminase structure, we speculated that YczR possibly possess half of the
alanine-glyoxylate transaminase activity. To test this speculation, we designed the UVabsorption and fluorescence spectroscopic experiments, and end-point enzymatic assays.
UV Absorption
To test potential YczR substrates, we designed UV-Vis spectroscopy experiments in which
20 amino acids and other possible substrate were added to the protein.
The UV absorption of YczR alone in the reaction buffer (50 mM HEPES, pH 7.5, 300 mM
NaCl) has two peaks maximum at 320 nm and 425 nm (Figure 19). The absorption curve stayed
unchanged in 20 mins measurement. The 330nm and 420 nm peaks of the Schiff base (aldimine)
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formed between an active-site lysine residue of the protein and PLP (Figure. 19, A) are generally
ascribed to a ketoenamine tautomer, enolimine tautomers, a substituted aldamine respectively or
PMP[64-68]. The peak at 420 nm signifies the formation of internal aldimine between an activesite lysine residue of the protein and PLP.

Figure 1. Time-resolved UV absorption spectra of YczR. 6 µM YczR in buffer (50 mM HEPES,
pH 7.5, 300 mM NaCl) containing 6 µM PLP was taken at 25°C in the absence (A) or presence
(B) of 500 mM L-alanine. After the addition of L-alanine, UV spectra were taken for 192
minutes at 2 mins intervals.
Upon mixing the YczR with 500 mM L-alanine, a biphasic spectral change was observed as
shown (Figures 19, B). In a time-dependent manner, a slow decrease in the 425 nm peak with a
concomitant increase in the absorbance at 325 nm was observed within 192 minutes.
Decrease of the absorption peak at 425 nm and increased that at 330 nm is consistent with
PLP turning into PMP. We speculated that L-alanine reacted with PLP to form one of the
intermediates of the half-transamination.
We speculate that the products of PLP and L-alanine reaction were PMP and pyruvate. UV
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absorption spectra of YczR-PLP showed an increase in absorption in the range of 300-320 nm in
reaction with L-alanine (Figure 19, B), suggesting the formation of PMP and possibly pyruvate,
which both has absorpt at 320 nm.
To prove one of the products was pyruvate, we added 100 mM pyruvate into the reaction
cuvette after YczR and L-alanine reaction completed (Figure 20, A). Upon addition of pyruvate,
the maximum absorption at 320 nm decreased (Figure 20, B). Moreover, maximum absorption at
425 nm increased at the same time (Figure 20, C). The absorption change suggested that
pyruvate was a product of PLP and L-alanine reaction. High concentration of pyruvate prompted
the product from the first half reaction (PMP) reacted with pyruvate producing L-alanine. The
increase in the UV absorption at 425 nm was observed during the addition of pyruvate, which
confirms the formation of the Schiff base (aldimine) between PLP and an active-site lysine
residue of the YczR. It is likely that that PLP-L-alanine reaction is a reversible reaction. Once the
concentration of the product is increased, it will promote PLP formation.

Figure 2. UV absorption spectra of YczR-L-alanine with pyruvate. Reaction of 6 uM YczR and
30 mM L-alanine should be completed in 192 mins. 100 mM pyruvate was added into the
cuvette. UV absorption was measured for 2 hours. Figures shown are for UV absorption change
in 300 nm-600 nm (A), 306nm-330nm (B) and 400-450 nm (C). Brown line indicates absorption
before addition of L-alanine. Pink line indicates that after PLP L-alanine reaction was complete.
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Specificity test of YczR with amino acids or small molecular

Figure 3. Specificity test of YczR with amino acids or other small molecules. Shown are UV
absorption changes of 7 µM YczR in the presence of 300 mM Arginine (A), Lysine (B), Serine
(C) and Leucine (D). In each case, the buffer was 50 mM HEPES, pH 7.5, 300 mM NaCl.
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Figure 4. Specificity test of YczR with amino acids or other small molecules. Shown are UV
absorption changes of 7 µM YczR in the presence of 300 mM phenyalanine (A), threoine(B),
valine (C) and methionine (D). In each case, the buffer was 50 mM HEPES, pH 7.5, 300 mM
NaCl.
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Figure 5. Specificity test of YczR with amino acids or other small molecules. Shown are UV
absorption changes of 7 µM YczR in the presence of 300 mM β-Alanine (A), GABA (B),
Glutamine (C) and Cysteine (D). In each case, the buffer was 50 mM HEPES, pH 7.5, 300 mM
NaCl.
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Figure 6. Specificity test of YczR with amino acids or other small molecules. Shown are UV
absorption changes of 7 µM YczR in the presence of 300 mM histidine (A), tyrosine (B), glycine
(C) and tryptophan (D). In each case, the buffer was 50 mM HEPES, pH 7.5, 300 mM NaCl.
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Figure 7. Specificity test of YczR with amino acids or other small molecules. Shown are UV
absorption changes of 7 µM YczR in the presence of 300 mM aspartic acid (A), asparagine (B),
proline (C) and D-alanine (D). In each case, the buffer was 50 mM HEPES, pH 7.5, 300 mM
NaCl.
The UV-visible spectrum of YczR reacted with other amino acids, and possible substrates
were recorded (Figure 21-25). The time-dependent UV absorption of 7 µM YczR-PLP with 300
mM Β-Alanine, serine, arginine, lysine, tyrosine, histidine, aspartic acid, phenylalanine, leucine,
proline, threonine, valine, GABA, tryptophan, asparagine, methionine, and glutamine was
measured separately in a cuvette with a 1 cm path length. The UV abortion spectral changes that
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occurred with the addition of L-alanine were not observed when other amino acids, such as the
D-alanine, glycine, glutamine or asparagine, were added. The results suggest that YczR
specifically reacted with L-alanine, which matches the purpose of YczR as it activates
transcription of the yczE operon. L-alanine or molecules with similar structure may regulate
YczR function though reaction with PLP.
Fluorescence emission spectra
More information about conformational changes of the Schiff base after addition of Lalanine can be obtained by fluorescence emission spectroscopy.
Time-dependent fluorescence emission spectra results of YczR with L-alanine is shown
(Figure 26). YczR (6 µM) and L-alanine (500 mM) were mixed in buffer (50 mM HEPES, pH
7.5, 300 mM NaCl) at 25 °C. After the addition of L-alanine, fluorescence spectra was taken for
20 mins at 4 mins intervals. When L-alanine-reacted YczR was excited at 283 nm, the
characteristic emission peaks of the Shiff base between PLP and lysine were observed at
approximately 326 nm[69].
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Figure 8. Fluorescence emmission spectra of YczR. Fluorescence spectra of YczR-PLP (1.4 µM)
in the buffer (50 mM HEPES, pH 7.5, 300 mM NaCl) was taken at 25°C in the absence of 500
mM L-alanine at an excitation wavelength of 283 nm.
Upon mixing the YczR with L-alanine, a change in fluorescence spectra was observed. The
peak in the absorbance at 326 nm decreased slowly. The 326 nm absorption peak of the Lalanine-reacted YczR can be ascribed to the external Schiff base associated with L-alanine.
These results suggest that the Shiff base formed between PLP in YczR was broken in the
presence of L-alanine.
The fluorescence spectral changes that occurred with the addition of L-alanine were not
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observed when other amino acids, such as the D-alanine, glycine, glutamine or asparagine, were
added.
Based on the results of Fluorescence emission spectra and UV absorption spectra, we
speculate that the internal aldimine of YczR can react with L-alanine specifically.
An End-point Assay to Monitor the YczR Catalyzed Half Transaminase Reaction
Based on the UV absorption spectra result, we speculate that L-alanine formed pyruvate
after reaction with PLP. An End-point assay was designed to confirm this hypothesis (Scheme 1).
YczR was incubated with L-alanine excess and coupled with a lactate dehydrogenase to monitor
the consumption of the NADH at 340 nm.
NH3+

O
O-

PMP +

O
Pyruvate

YczR

O-

+ PLP

O
Alanine

NADH
Lactate Dehydrogenaase
NAD+
O
OOH
Lactate

Scheme 1. The end-point YczR-catalyzed half-aminotransferase reaction. The first half reaction
(L-alanine to pyruvate) of the YczR-catalyzed transamination is shown on the top. The second
half-reaction of Lactate dehydrogenase-catalyzed NADH oxidization is shown at the bottom.
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To let the L-alanine and PLP reaction to be completed, 1 µM, 3.5 µM and 7 µM YczR had
been added in the reaction buffer containing 500 mM L-alanine, 50 mM HEPES, (pH7.5), 300
mM NaCl, which was kept at room temperature for 15mins. The lactate dehydrogenase
consumed all pyruvate in each reaction solution to produce lactate. The data above shows
measured absorbance change at 340 nm from the concomitant oxidation of the cofactor, NADH
to NAD+.
The concentrations of protein should affect the starting absorption points. The higher
concentration of YczR in reaction solution had a higher starting absorption point. The absorption
of 1 µM, 3.5 µM and 7 µM YczR decreased by 0.01, 0.05 and 0.1, absorption units (Figure 27).
Those results suggest that 1 µM PLP in the YczR solution could react with 1 µM L-alanine to
produce 1 µM pyruvate. In the YczR-catalyzed first half aminotransferase reaction, PLP and
PMP are in dynamic equilibrium when pyruvate is present. All of the PLP was converted to PMP
when pyruvate was omitted.
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Figure 9. An end-point assay to monitor catalysis of half transaminase reaction by YczR.
Absorption changes of NADH in the presence of 1 µM (blue), 3.5 µM (red) and 7 µM (black)
YczR. 1 µM, 3.5 µM and 7 µM YczR has been added in the reaction buffer containing 500 mM
L-alanine, 50 mM HEPES, (pH7.5), 300 mM NaCl, which was kept at room temperature 12
hours. The lactate dehydrogenase consumed all pyruvate in each reaction solution to produce
lactate. Absorbance change at 340 nm from the concomitant reduction of the cofactor, NADH to
NAD+ was measured.

CHAPTER FOUR
YCZR BINDS DNA SEQUENCE BETWEEN YCZR GENE AND YCZE GENE IN A
SIMILAR FASHION TO GABR
YczR Binds DNA with High Affinity
YczR DNA binding sites and binding affinity was determined via fluorescence polarization
(FP) experiments[70]. The K. pneumoniae YczR regulatory region contains 88 bp and has two 5bp
direct repeats (CCTCA & AATGG).
5’ATTTTTTCCTCAACATCATTGCGAATGCCCTCATCATCAGCAAAAATGGACTG
ATAATTAATGGCCAGTTTTGGAAAAGTGGATCGCT3’ within this fragment, the two
direct repeats of sequences CCTCA and AATGG, appear to be likely for YczR binding. The
bindings sites between CCTCA and AATGG repeats are separated by 34 bp, which corresponds
to approximately three helical turns of DNA. Therefore, the corresponding nucleotides of the
binding sites should lie on the same face of the DNA helix.
GabR protected a 49 bp region of DNA identified previously for GabR-dependent
regulation in vivo[35, 36]. Sequence alignment results indicate that many residues of the DNA
binding regions between GabR and YczR are conserved (Figure 28). The GabR and YczR DNA
binding regions are similar in type, direction, and spacing. We predict that some protein-DNA
interactions between GabR-DNA and YczR-DNA complexes will be similar. Although a
multitude of GntR family DNA bindings sites has been determined, the studies did not indicate a
clear consensus sequence, rather sparse alignment was detected over short fragments [54, 55, 71].
44
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Based on the pair of two direct sequence repeats, two 68-bp complementary single-stranded
DNA oligonucleotides containing the YczR binding region
(5'TTTCCTCAACATCATTGCGAATGCCCTCATCATCAGCAAAAATGGACTGATAATTA
ATGGCCAGTTTT-TAMRA-3', where Fl means fluorophore) were purchased from Integrated
DNA Technologies (IDT). Fluorescence polarization assay studies were conducted to estimate
1nM as the optimal DNA concentration for further experimentation.

Figure 1. Sequence alignment of the winged-helix domain sequences of B. subtilis GabR gabRgabT DNA binding regions (top) and K. pneumoniae YczR yceE DNA binding regions (bottom).
The black asterisks highlight DNA-binding residues of YczR that are identical or similar in
GabR.
The binding affinity of YczR for DNA containing the 68-bp YczR binding site was
determined by FP (Figure 29). Different concentrations of YczR were incubated with TAMRAlabeled DNA fragments containing the promoter regions of yczE and assayed for the formation
of protein-DNA complexes. The result showed a dose-dependent polarization increase, indicative
of YczR binding to DNA. The fluorescence polarization data set was fitted into the modified Hill
equation to determine the apparent dissociation constant of the YczR-DNA complex, as 26.47
nM.
To rule out nonspecific effects from the TAMRA label and establish binding specificity, a
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negative control assay was performed with Bovine Serum Albumin (BSA) and the TAMRAlabeled DNA (Figure 30). A constant concentration of TAMRA-labeled DNA was incubated in
several aliquots with increasing concentrations of BSA protein. The fluorescence polarization did
not show any significant change with increasing concentration of BSA, which suggests that
YczR specifically binds to the TAMRA-labeled DNA.
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Figure 2. Fluorescence polarization assays to measure DNA binding by YczR. Titration of YczR
against 1 nM TAMRA-DNA. The YczR concentrations were varied from 0 to 3,000 nM. The
average values and errors were plotted and fitted to the Hill equation. Each data point was
measured in triplicate. Error bars are too small to be displayed if the errors are less than
1/1,000th of the measured value.
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Figure 3. Specificity test of YczR fluorescence polarization assays. In the negative control
binding assay, the same increasing concentrations BSA were used against a fixed concentration
of TAMRA-labeled DNA to indicate specific binding.
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YczR likely binds to the regulation region with a 2:1 stoichiometry
Based on the CCTCA and AATGG direct repeats on the DNA sequence, two 34-bp
complementary single-stranded DNA oligonucleotides containing the YczR binding region
DNA_1 (5'- TTTCCTCAACATCATTGCGAATGCCCTCATCATTC-TAMRA-3') and DNA_2
(5'- AGCAAAAATGGACTGATAATTAATGGCCAGTTTT-TAMRA-3') were designed and
purchased from IDT. The two 34 bp DNA fragment located within the YczR protected region is
close in size to a minimal fragment allowing YczR binding in vitro.
YczR binds tighter to the site closer to yczE gene
DNA_1 has one specific binding site for YczR (Figure 31). The dissociation constant (Kd)
of the YczR with DNA_1 complex was determined to be 135.1 nM. DNA_2 also has one
specific binding site for YczR (Figure 32). The dissociation constant (Kd) of the YczR with
DNA_2 complex was determined to be 33.63 nM. We speculate that YczR binds on the DNA_2
binding site first at low concentration and then it binds the DNA_1 binding site at high
concentration.
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Figure 4. Fluorescence polarization assays to measure DNA_1 binding by YczR. Titration of
YczR against 1 nM TAMRA-DNA. The YczR concentrations were varied from 0 to 3,000 nM.
The average values and errors were plotted and fitted to the Hill equation. Each data point was
measured in triplicate. Error bars are too small to be displayed if the errors are less than
1/1,000th of the measured value.
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Figure 5. Fluorescence polarization assays to measure DNA_2 binding by YczR. Titration of
YczR against 1 nM TAMRA-DNA. The YczR concentrations were varied from 0 to 3,000 nM.
The average values and errors were plotted and fitted to the Hill equation. Each data point was
measured in triplicate. Error bars are too small to be displayed if the errors are less than
1/1,000th of the measured value.
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Materials and Methods
Materials
Chemicals for YczR purification, crystallization, assays were purchased from SigmaAldrich (St. Louis, MO), Alfa Aesar (Tewksbury, MA) and Fisher Scientific (Pittsburgh, PA).
YczR gene was synthesized with codon optimization for E. coli expression from Integrated DNA
Technologies (Coralville, IA).
E. coli BL21 (DE3) cells and Turbo cells were purchased from New England BioLabs
(Ipswich, MA). Bacterial growth media Luria-Bertani (LB) broth and antibiotics were obtained
from Sigma-Aldrich. Crystallization screen solutions and other crystallization supplies were
purchased from Hampton Research (Aliso Viejo, CA) and Emerald Bio (Bedford, MA). All other
materials were purchased at the highest quality available. DNA and protein sequences were
analyzed using DNA Strider and the BLAST program[72, 73].
Methods
DNA Cloning. To construct the His-tagged version of the YczR protein, the coding region
was amplified by PCR from the synthesized YczR gene for K. pneumoniae genomic DNA using
the specific oligonucleotides as primers (forward primer designed as
GAAGGAGATATACATATGATCGACCAGAGCGATTGGATA and the reverse primer
designed as GTGATGGTGGTGATGATGATCCCCTGTAACGGGGATTTT). The PCR
thermocycler program used included an initial denaturation for 120 s at 95 °C; 40 cycles of 95 °C
for 30 s, 50 °C for 60 s, and 72 °C for 50 s; and the final extension of 72 °C for 5 min. The PCR
product was digested with NdeI and NotI and subsequently cloned into the expression vector
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pETite (Lucigen).
The YczR DNA fragment was cloned into the NdeI site of pETite by treated with Phusion
HF DNA polymerase, following the manufacturer's instructions. The pETite-kan-c-5His vector
with K. pneumoniae YczR full-length gene was transformed insert into E. coli Turbo competent
Cell (New England Biolabs).
After pETite-kan-c-5His vector was purified from E. coli Turbo cell, the resulting plasmid
was then transferred to competent E. coli BL21DE3 cells to overexpress the YczR protein.
Digestion of the plasmid from E. coli Turbo cell was by DNA Restriction enzymes NdeI and
NotI. The restricted DNA fragments were analyzed by agarose gel electrophoresis according to
standard protocols.
The purified plasmid from BL21DE3 cell was then sent to sequencing. DNA sequencing
result from DNA Sequencing & Genotyping Facility (University of Chicago Comprehensive
Cancer Center) confirmed the correct orientation with a C-terminal His6-tag.
Protein Purification. The YczR protein from E. coli was expressed and purified by using
the intein-mediated purification with an affinity histidine tag system. Transformed E. coli
BL21DE3 cultures were grown overnight at 37°C and 250 rpm in 500 ml of LB medium
containing 50 µg/ml kanamycin.
Induction of YczR expression was carried out at OD600 of 0.8 by adding Isopropyl-β-Dthiogalactopyranoside (IPTG) to the final concentration of 0.5 mM.
Cells were incubated at 25 °C and harvested after 16 hours by centrifugation at 7000 RPM
and 4 °C for about 15 min (Avanti J-E Centrifuge, Beckman Coulter). The cell pellet was
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resuspended in Ni column buffer containing 5% (vol/vol) glycerol and 1 mM PLP.
Following sonication (Qsonica sonicators, Q500 Sonicator) to break the cellular wall, the
cell extract was cleared by centrifuged twice at 16,500 rpm and 4 °C for 20 min. The supernatant
fraction was loaded onto a 10 ml affinity chromatography Ni-NTA column (GE Healthcare)
containing Ni2+ and previously equilibrated with lysis buffer. Elution of the retained proteins was
achieved with a linear imidazole gradient (20 column volume, 10 mM-400 mM).
Fractions containing protein eluted from Ni column were concentrated (Centricon Plus
centrifugal filter units; Millipore) to 2 mL, and loaded onto the gel filtration column (HiLoad
16/60 Superdex 200 pg. GE Healthcare), which was equilibrated with gel filtration column
buffer (300 mM NaCl, 50mM HEPES, pH 7.5).
The YzcR concentration was determined with the Bio-Rad protein assay kit. The protein
molecular weight was analyzed using Sodium Dodecyl Sulfate Polyacrylamide Gel
Electrophoresis (SDS-PAGE). Purified YczR protein was used freshly after exchanging into
suitable buffers for the crystallization and biological assays. The YczR protein was stored with
high salt concentrations (300 mM Nacl) and 5 % imidazole to stay soluble without precipitation.
The protein was stored at 4 °C for short-term or flash frozen in1000µL aliquots in liquid nitrogen
after the addition of 20% (V/V) glycerol and stored at -80°C for long-term use. The color of
concentrated, purified YczR was pale yellow because PLP was bound to the protein.
Crystallization. The purified YczR was buffer exchanged into crystallization screening
buffer (50 mM HEPES, pH 7.5, 300 nM NaCl) and concentrated to 10 mg/ mL using a 10,0000
molecular weight cutoff (MWCO) Amicon-Ultra centrifugal filter device (Millipore). The initial
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sparse matrix screen (Crystal Screen Cryo 1 and 2, Crystal Screen 1 and 2, Index 1 and 2, and
PEG/Ion 1 and 2 from Hampton Research and Wizard 1&2 and 3&4 from Emerald BioSystems)
were set up with the Gryphon crystallization robot (Art Robbins Instruments) to obtain initial
crystallization hits.
Crystals appeared in the well solution containing 20% (W/V) PEG8000, 100 mM HEPES,
pH 7.5, 200 mM (NH4)2SO4, and 10% (V/V) isopropanol after a week during incubation at room
temperature. After the initial crystallization screen, Crystals of YczR were obtained via the
sitting drop methods incubated at room temperature. Further optimized manually using a 1:1 well
solution: YczR stock solution (10 mg/mL) ratio to obtain crystals with the best size and
morphology. Crystallization was conducted in 24-well Cryschem sitting drop plates (Hampton
Research). Crystals grew to maximum size in 1-2 weeks and were harvested in about 15 days.
For attempted co-crystallization of YczR and L-alanine, 6 µL of YczR (20 mg/mL) was
mixed with 1 µL of 10 mM L-alanine (dissolved in protein crystallization buffer) with 4 µL of
well solution containing 8% (V/V) Tacsimate, pH 6.0, 20% (W/V) PEG8000. Crystals were
seeded on day 3 with crystals obtained from previous trials. Crystals with good size and
morphology were picked directly from the sitting drops into a cryoprotecting solution (well
solution supplemented with 25% (v/v) glycerol) and then flash-cooled in liquid nitrogen.
X-ray Diffraction Data Collection. Individual YczR crystals were flash frozen in liquid
nitrogen using 30% PEG10,000 in the crystallization buffer as a cryoprotectant solution. The
diffraction data of YczR were collected at Advance Photon Source (Argonne National
Laboratory, Argonne, IL) Structural Biology Center (SBC) 19ID and 19BM beamlines. The
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YzcR crystal diffraction images were recorded by the 4×4 tiled 300×300 mm2 sensitive area
CCD detector from Area Detector Systems Corp. (ADSC). The data collection was at a
wavelength of 1.0 Å. The datasets were indexed, integrated and scaled using the HKL2000[74].
Structure Determination, Model Building, and Refinement. The collected datasets were
all scaled in the space group C2221 to a resolution of 1.79 Å. Auto build by molecular
replacement using PHASER[75] in the PHENIX[76] software suit automatically built about 60% of
the residues. Manually build the remainder of the model in COOT[77]. Rigid body refinement
followed by restrained refinement was carried out in Refmac5 in the CCP4 software suits until
no more side chains can be built in automatically[78]. Final refinement statistics of YczR are
listed in Table 1. Structural figures were made using UCSF Chimera[79].
UV-Absorption Spectroscopy. UV-Vis absorption spectra were recorded with Jasco V550 spectrophotometer in 1 mL quartz cuvettes in 50 mM Tris-HCl, pH 7.5, and 300 mM NaCl
at 25 °C. The enzyme solution was centrifuged 5 mins at 14,000 RPM to reduce light scattering
from the small amount of precipitate. The protein solution contained 10 mM potassium
phosphate buffer at pH 7.5.
Absorption of YczR-PLP (7 µM) with L-alanine (50 mM) was observed in the UV range
300-600 nm over time. Also measure YczR-PLP (7 µM) at various with 300 mM Β-Alanine, Lserine, Arginine, Lysine, Tyrosine, Histidine, Aspartic acid, Phenylalanine, Leucine, Proline,
Threonine, Valine, GABA, Tryptophan, Asparagine, Methionine, and Glutamine separately as
the same as YczR and L-alanine experiment.

57
End-point Assay to Monitor the YczR Catalyzed Half Transaminase Reaction.
Activity was measured using varying concentrations of YczR protein in an assay buffer
containing 50 mM HEPES (pH 7.5), 300 mM NaCl, 500 mM L-alanine, 320 µM NADH, and 5
units Lactate dehydrogenase (LDH).
In the first half-reaction, add 1 µM, 3 µM and 7 µM YczR to 500 µM L-alanine overnight at
room temperature. In the coupled assay, measure the amount of pyruvate produced from each
tube. LDH consumes the product of the first half-reaction (pyruvate) to produce lactate. The
coupled reaction is measured spectrophotometrically (absorbance change at 340 nm) from the
concomitant oxidation of the cofactor, NADH to NAD+.
Fluorescence emission spectroscopy. Fluorescence emission spectroscopy is a type of
electromagnetic spectroscopy, which analyzes fluorescence from a sample. Experiments were
performed using a PTI Quanta-Master fluorimeter (Photon Technologies, Mirmingham, NJ).
Time-based assays were conducted with excitation and emission wavelengths set at 283 and 326
nm, respectively. The measurement was initiated after 1.4 µM YczR-PLP and in the presence of
500 mM L-alanine in the buffer containing 50 mM HEPES (pH 7.5), 300 mM NaCl.
Fluorescence emission spectra were measured every 4 mins from 0 min to 20 mins at 25 °C.
GraphPad Prizm 3.0 was used for analyzing the time-dependent curves.
Size Exclusion Chromatography with Multi-Angle Light Scattering (SEC-MALS). The
size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) was used
to determine the molecular mass of YczR oligomers in solution. SEC-MALS system was set up
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with the AKTA FPLC system (GE Healthcare Biosciences) with a silica-based size-exclusion
chromatography column (WTC-030S5, Wyatt Technology) as a liquid chromatography unit.
For the experiments, the column was connected upstream of a refractive index detector
(Optilab TrEX, Wyatt Technology), and then followed by a multiangle light scattering detector
(Dawn Heleos II, Wyatt Technology) used for determining protein concentration and particle
size, respectively.
SEC-MALS sample injection requires 100 µl of a solution containing 7 µM YczR protein in
50mM HEPES (pH 7.5), 300 NaCl buffer. The flow rate was set at 0.4 mL/min, and data were
collected at 2 s intervals. Data processing and analysis were performed by the ASTRA software
(Wyatt Technology).
Fluorescence Polarization Assay. The binding affinity of YczR for a DNA containing the
68-bp YczR binding site was determined by fluorescence polarization assays[70]. Synthesis
Labeled DNA Sequence with fluorophore from Integrated DNA Technologies (IDT)
Two 68-bp complementary single-stranded DNA oligonucleotides containing the YczR
binding region (5'- TTTCCTCAACATCATTGCGAATGCCCTCATCATCAGCAAAAATGG
ACTGATAATTAATGGCCAGTTTT-TAMRA3', where Fl means fluorophore) were purchased
from Integrated DNA Technologies (IDT).
Based on the four direct repeats on the DNA sequence, two 34-bp complementary singlestranded DNA oligonucleotides containing the YczR binding region (5'- TTTCCTCAACAT
CATTGCGAATGCCCTCATCATC-TAMRA-3') and (5'-AAAACTGGCCATTAATTA
TCAGTCCATTTTTGCT-TAMRA-3') were also purchased from IDT.
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Both oligonucleotides were synthesized and labeled with the fluorophore,
carboxytetramethylrhodamine (TAMRA) attached at the 3' terminus. TAMRA has an emission
maximum of 580 nm and an absorbance maximum of 565 nm.
The double-stranded oligonucleotides were prepared by annealing a mixture containing an
equimolar concentration of the two single-stranded oligonucleotides at 25 µM in 10 mM TrisHCl, pH 8.0, 1 mM EDTA, and 50 mM NaCl. The annealing solution was heated at 90°C for 1
minute, and then cooled 5°C per minute until it reached 10°C by using a Mastercycler Personal
(Eppendorf).
For the fluorescence polarization assay, YczR was serially diluted in the buffer (50 mM
HEPES, pH 7.5, 5% Glycerol, 300 mM NaCl) to acquire the appropriate concentrations against a
fixed concentration of TAMRA-labeled DNA (1 nM).
The constant concentration (0.1 nM) of TAMRA-labeled DNA was mixed with the serially
diluted YczR protein (final concentration, 0-1,000 nM). The DNA binding reaction contained 50
mM HEPES, pH 7.5, 10 mM MgCl2, 0.1 µg/µL BSA, 100 mM NaCl, and various concentrations
of protein typically in 100 µL. The sample mixture was loaded into the individual wells of a 384well micro-plate. Fluorescence polarization data for the YczR DNA complex were obtained
using a BioTek Synergy 2 Plate Reader (BioTek). The fluorescence polarization (FP) signals of
the YczR-DNA mixtures were measured with fixed excitation (531 nm) and emission (595 nm)
wavelength filters at room temperature. In the negative control binding assay, Add Bovine serum
albumin (BSA) at increasing concentrations against a fixed concentration of TAMRA-labeled
DNA.
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The change plots in mP as a function of YczR concentration were used to determine the
equilibrium dissociation constant (Kd) for the interaction between YczR and DNA binding site.
The data was fit to a hyperbola using the program Kaleida Graph (Synergy Software). Determine
Kd by: (Bmax)([S])/Kd+[S], where Kd and Bmax are derived from the single-ligand binding
plot, and [S] is the concentration of the fluorescein-labeled DNA. Use the Kd result to calculate
the Ki using the following equation: Ki=EC50/ (1+[s])/kd, where Kd is for YczR binding to
DNA sequence.

CHAPTER FIVE
CONCLUSIONS AND FUTURE INVISTIGATIONS
Many widespread DUFs are biologically essential in bacteria, and the importance of
understanding and prioritizing DUF research has been recognized in the last few years[80]. DNA
sequence alignment results have indicated that YczR in K. pneumoniae is the transcriptional
regulator of YczE (DUF161) a new MocR/GabR subfamily member of the GntR superfamily.
In this study, we have defined two X-ray structures of the YczR regulation domain: a 1.79
Å structure with PLP bound and a 2.0 Å apo structure without PLP.
To the best of our knowledge, these structures are the first YczR X-ray crystal structures
solved. The elucidation of the three-dimensional YczR crystal structure provided important
information regarding the structure-function relationship and domain arrangements of the
MocR/GabR subfamily. Additionally, this information allowed for transcriptional activity
analysis of YczR.
GabR is the best genetically and biochemically characterized MocR/GabR subfamily
member. The members of the MocR/GabR subfamily contain an N-terminal wHTH DNAbinding domain and a C-terminal aminotransferase-like PLP binding domain. YczR and GabR
belong to the same evolutionary subgroup the MocR/GabR subfamily and share similar
mechanistic, functional, and structural features.
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The N-terminal helix-turn-helix DNA-binding domain was not found in the two YczR
crystal structures. However, SEC-MALS and mass spectrometry results suggested that the YczR
protein is full length in solution after purification. We speculated that YczR lost the DNAbinding domain during crystallization, likely due to a contaminated protease activity. Although
YczR and GabR are similar in molecular weight, the SAXS results indicated that YczR occupies
a greater volume. We surmise that the interactions between the DNA binding domain and the
regulation domain within YczR are weaker than in GabR. This allows for full extension of the
linker region, which contributes to the loss of the DNA binding domain during crystallization.
Similar to GabR, YczR has a co-factor, PLP, which is a common co-enzyme among a large
number of enzymes. Also, like GabR[36], the YczR structure shown indicates that the ε-amino
group of lysine331 forms a covalent Schiff base linkage (internal aldimine) with the aldehyde
group of PLP; which serves as the only effector of the YczR. In contrast, GabR requires GABA
for modulation of its activity in addition to PLP[54]. Based on Belitsky’s publication, the
intracellular level of PLP in bacteria is most likely not subject to significant variations[54]. It is
unusual among bacterial transcriptional regulators to require a B6 vitamin for activity
modulation.
YczR is a likely DNA-binding transcription regulator that requires the presence of PLP for
activation of the yczE promoter. YczR binds DNA sequence between yczR gene and yczE gene
in similar fashion comparing to GabR. From the fluorescence polarization results, it appears that
an oligomeric form of YczR binds to two binding sites within the yczE gene. The YczR can
recognize and specifically bind to sequences within the yczE promoter fragment.
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YczR likely binds to the regulation region with a 2:1 stoichiometry. The dissociation
constant (Kd) of the YczR-DNA complex was determined to be 26.47 nM. Although the precise
stoichiometric binding of YczR for DNA is unknown, the dissociation constants which been
determined from the fluorescence polarization assay suggest that YczR binds DNA with a high
affinity. Four direct repeats of the sequence CCTCA and AATGG were located in this fragment,
which appears to be essential for YczR binding. YczR binds tighter to the site closer to the yczE
gene.
YczR regulation domain catalyzes a reversible half-transaminase reaction instead of being a
non-enzymatic regulator like GabR. The only documented role of PLP as a cofactor in numerous
enzymes is catalytic[81]. As such most of the aminotransferases are involved in the metabolism of
amino group-containing compounds [42, 45]. It seems likely that PLP plays the same type cofactor
role in YczR as it does in GabR. The aminotransferases PLP-binding domains evolved
specifically to catalyze the aminotransferase reaction[46, 82, 83]. The UV-visible spectrum and
fluorescence emission spectra results suggested the possibility that the regulatory domain of
YczR maybe positive regulation of transcription because it could catalyze the half enzymatic
reaction involving PLP.
Previous research efforts have shown that potent mechanism-based in-activators can be
rationally designed against these PLP-dependent drugs-targets. Although the mechanistic
function of PLP cofactor has been studied in details, its transcriptional regulator role has not
been fully elucidated[54]. Our current research results will contribute to understanding the role of
PLP in the K. pneumoniae YczR transcriptional regulator domain. We propose several possible
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functions for the 330 amino acids long PLP-binding aminotransferase-like regulator domain of
YczR can be suggested: (1) it has a structural role to maintain oligomerization overall and/or
stability; (2) it is an effector-binding domain; (3) it likely performs an enzymatic reaction
unrelated to regulatory functions and the DNA-binding of YczR; it may catalyze an enzymatic
reaction, which is essential to exert its regulatory functions of YczR.
PLP also may interact covalently with taurine to activate TauR[55]. YczR likely responds to
alanine to regulate taurine trafficking in K. pneumoniae to facilitate infection in animals and
humans.
Taken together, all the results from UV absorption and half alanine-glyoxylate transaminase
assay indicate that the YczR is highly specific for catalyzing L-alanine to pyruvate processing,
thereby playing a pivotal role in L-alanine detoxification. In this half-reaction, the L-alanine
reacts with PLP and transfers its α-amino group to PLP to make pyridoxamine phosphate (PMP).
A new Schiff base is generated once the L-alanine interacts with the PLP commonly referred to
as the external aldimine[36]. If in the complete transaldimination reaction, then PMP would
transfer its nitrogen to the sugar to make an amino sugar. However, the crystal structure of YczR
showns that PMP had been released from the regulation domain active site pocket.
L-alanine could have specificity affected to YczR-DNA interaction. It may affect YczRDNA interactions though PLP. The use of a variety of biochemical techniques has allowed us to
gain an in-depth understanding of the characteristics of YczR.
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Future Work
YczR monomer’s molecular weight is 52.2kDa. YczR should be full-length protein in
solution depend on mass spectrometry result. To research the selectivity and reaction
mechanisms of YczR, future studies could involve active site residues mutations in YczR. Fulllength YczR is not very stable at room temperature and low salt concentration solution. DNA
binding domain of YczR would be moved to make truncated YczR protein.
DNA foot printing is a method to determining the DNA sequence specificity of DNAbinding proteins binds in vivo or in vitro. YczR is the transcriptional activator controlling the
transcription of YczE (DUF161). The localization of YczR DNA binding sites would elucidate
the function of YczE.
Many years of the alarming rise of bacterial resistance and antibiotics abuse has created a
dangerous quandary for antibiotics research. Advances in the development of the scientific
technology, and more tools have been provided for the improvement of the already established
antibiotics and the new antibiotic classes discovery. The research of YczR maybe used to design
inactivators, which are specific for drug targets to combat the rise of resistant gram-negative
pathogens.

CHAPTER SIX
THE AQUEOUS DECAY OF A VANADIUM COMPLEX SEREDIPUOSLY REVEALS
MISSING KNOWLEDGE ON THE REDOX STATES OF PTP1B
Research aims: The decay of a vanadium complex and its redox effect on PTP1B, a target
for diabetic treatment, in vitro
Diabetes is the seventh leading cause of death in the United States in 2016. The Center of
Disease Control (CDC) and the American Diabetes Association (ADA) published the Diabetes
Report Card in 2014, stating that 29.1 million Americans are diagnosed with diabetes as of
2012[84]. There are two major types of diabetes with , which people are diagnosed, type 1 and
type 2.
Type 1 diabetes is genetically inherited and occurs when insulin is not produced in
sufficient quantities. In type 2 diabetes, the insulin is produced in standard quantity, but the
insulin receptors are desensitized and unable to transmit the signal inward to the cell[85, 86]. Type
2 diabetes is often seen in patients with unhealthy lifestyles and is of interest due to the
prevalence of patients with heart disease[87].
Protein-tyrosine phosphatases (PTPs) are a class of enzymes that regulate a variety of
fundamental cellular processes[88, 89]. PTP1B is a critical negative regulator of leptin signaling
pathways[90, 91]. Protein Tyrosine phosphatase 1B (PTP1B) was the first PTP purified from
human tissue[92].
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Previous studies have indicated that PTP1B plays an important role in cell signaling
relevant to diabetes, obesity, and cancer[92-94]. PTP1B is a critical negative regulator of leptin
signaling pathways[90, 91]. PTP1B also is a key negative regulator of insulin signaling pathways,
which inhibit the pathway responsible for controlling the uptake of glucose into the cell and
lowering blood sugar levels[95]. Inhibition targeting PTP1B could prove to be effective in the
treatment of type 2 diabetes and provide an opportunity to improve insulin sensitivity[84, 96].
However, the difficulty lies in identifying a specific, potent and safe PTP1B inhibitor. The two
major challenges in developing potential therapeutics targeting PTP1B are lack of selectivity
over other similar PTPs as well as lack of cell permeability[97]. Developing PTP1B inhibitors
should simultaneously occupy both active site (Site-A) and the adjacent pTyr binding site (SiteB) partially to address the selectivity issue[98].
Vanadium compounds have been known to be insulin-enhancing agents both in vitro and in
vivo[99]. Orthovandate (VO43-), the vanadate form which most closely mimics PO43-, can act as a
substrate analog to inhibit all types of phosphatases because it shares similar structural properties
with phosphorus[100].
Organic vanadium complexes have been proven more effective in vivo and in vitro studies
than inorganic vanadium compounds[101]. It has been demonstrated that the peroxovanadium
compounds irreversibly oxidize the thiol group of the conserved catalytic cysteine in the PTP
catalytic sites[102]. Various vanadium compounds may have a different but overlapping spectrum
of PTP inhibition activities, due to differences in their structure and stability. Vanadium is not
well absorbed by mammalian cells, while some organic vanadium complex are better absorbed
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because of the favorable membrane permeability[99, 103]. The detailed mechanisms by which
different vanadium complexes enhance insulin’s activity are still not fully understood[104, 105].
Another specific product generated during this decay and their effects on PTP1B was not
looked at carefully. The prevalent explanation is that vanadium compounds would break down in
solution and inhibit PTP1B activity via the generated vanadate acting as a transition state analog
in the PTP1B reaction[102, 106, 107].
Vanadyl acetylacetonate, VO(acac)2 is an organo-vanadium complex, where (acac) is the
conjugate base of acetylacetone[108]. VO(acac)2 has been shown to inhibit tyrosine phosphatases
(PTPases), such as PTP1B[107]. Like other charge-neutral acetylacetonate complexes, it is more
soluble in polar organic solvents.
This work will focus on the co-crystallization and inhibition of PTP1B using synthesized
VO(acac)2 complex (Figure 33). In addition to vanadium complexes having shown potential in
the treatment of Type 2 diabetes, other studies indicated shown that some zinc complexes also
have similar insulin-enhancing effect in treatment of type 2 diabetes[109].
Besides the drug design effort, the oxidation state of the catalytic cysteine in the PTP1B
activity down regulation still presents some unsolved puzzles. Robin Carr & Harren Jhoti found
that after soaking PTP1B with 2-phenl-sioxazolidine-3, 5-dione, the sulphur Sγ atom of Cys-215
formed a covalent bond with the backbone nitrogen atom of Ser-216[110]. In our studies, it was
observed that while Cys-215 was oxidized; it did not form a covalent bond with the backbone
nitrogen atom of Ser-216, representing a possible intermediate state in redox sensing.
In this study, we report the crystal structure of inhibited PTP1B obtained from the co-
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crystallization experiment of PTP1B and VO(acac)2. In addition to the inhibited structure via a
vanadate species, the catalytic Cys-215 is shown to be partially oxidized and in two alternative
conformations. Combining both inhibition studies and the crystal structures present important
gap knowledge in the modification/oxidation of the PTP1B via the aqueous decay of VO(acac)2.

Figure 1. Synthesis of VO(acac)2 complex.
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Results and Discussion
A variety of structural, enzymatic and kinetic studies from several laboratories have made
clear that the mechanism of PTPs substrate recognition and catalysis[111-113]. All members of the
PTPs are characterized by the presence of a signature motif, which contains the cysteine residue
(Cys-215 in PTP1B) that is essential for catalysis[112]. PTP-mediated catalysis proceeds via a
two-step ping-pong mechanism (Scheme 2).

Scheme 1. The general mechanism of the PTP-catalyzed reaction. The WPD-loop assumes a
catalytically active closed conformation with the general acid in position to protonate the leaving
group during formation of the phosphor-enzyme intermediate. In the second step this
intermediate is hydrolyzed. After the phosphate product is released the WPD-loop open
conformation becomes favored.
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In the first step, a nucleophilic sulfur atom of the thiolate side chain of the cysteine attacks
the phosphate ester moiety of the substrate, resulting in the formation of a phosphor-enzyme
intermediate with the release of the peptidyl-tyrosine. The second step occurs via the
phosphoenzyme intermediate attacked of a water molecule, which mediated by Asp-181 and
Gln-262, yields the final products inorganic phosphate and the regenerated enzyme.
Structure of PTP1B and VO(acac)2 Complex
The X-ray structures for PTP1B in the presence of the competitive inhibitor vanadate was
determined by molecular replacement and refined to a 2.2 Å resolution. Overlapping X-ray
crystal structures of PTP1B as ribbon diagram with VO(acac)2 as a ribbon diagram is shown
(Figure 34).
The PTP1B crystal structure to be solved was that of the 37kDa PTP1B catalytic domain
with VO(acac)2 complex. PTP1B is one of the 38 classical PTPs that specifically target
phosphorylated tyrosine residues. It is composed of an N-terminal catalytic domain, two prolinerich motifs, and a C-terminal hydrophobic region. The crystals belong to P21 space group with
cell dimensions (a= 52.17 Å, b = 71.75 Å, c = 88.01 Å) diffracted to 2.2 Å. The vanadium
compound engages the catalytic site of the PTP1B protein.
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Figure 2. Overlapping X-ray crystal structures of PTP as ribbon diagram 1B with VO(acac)2 as a
ribbon diagram.
The electron density of residues revealed the presence of covalently bound Vanadate in the
pocket situated at the interface of the subunits in the crystal structure of PTP1B (Figure. 35). It is
of interest to note that the structure of the initial Vanadium complex had degraded before the
actual binding of the inhibitor to PTP1B. The pocket also corresponds to the cofactor binding
sites in the related enzymes and therefore defines the active site of PTP1B.
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Figure 3. Electron density of the vanadate modified catalytic cysteine. Vanadate is shown with
the refined 2Fo-Fc electron density map contoured at 1.0 σ.
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Table 2. Crystallographic data collection and refinement statistics for PTP1B
PTP1B
Space group
Cell dimension
α, β, γ (deg)
a, b, c (Å)
Resolution (Å)
Resolution at I/σ (I) =2
R (%)
I/σ (I)
CC ½
Completeness (%)
Multiplicity
No. Reflections
No. Unique Reflections

P21

R /R (%)
No. of Atoms
protein
ligand
water
B factors (Å )
protein
ligand
RMSD
bond lengths (Å)
bond angles (deg)
Ramachandran plot (%)
most favored
allowed
outliers

17.7/22.6

a

pim

b

c

work

d

free

60.743, 61.26, 88.307
90.0, 90.041, 90.0
1.83
1.90
5.8(43)
12.3(8.3)
0.673
91.1(83.4)

13937
66
1400

2

29.135

e

a

0.02
1.96

Precision-indicating merging R
Pearson correlation coefficient of two “half”data sets
c
Rwork = Σ|Fobs − Fcalc|/ΣFobs
d
Five percent of the reflection data were selected at random as a test set, and only these data were used to calculate Rfree
e
Root-mean square deviation
h
Not applicable
b

75
The Electron Density in Green is the simulated annealing omit difference map (2Fo-Fc), at
1.0 sigmas, that shows the existence of orthovanadate (VO43-). The central vanadium atom of
orthovanadate is covalently linked to the sulfate of Cys-215. The Electron Density in grey is the
simulated annealing composite map (2Fo-Fc) showing sulfenic acid, which is oxidized at the
Cys-215 residue and exists in 2 positions at 1.0 sigma.
From the omit map, the thiol group on Cys-215 has been oxidized. The side chain exists in
two conformations, with one bound to Vanadate and the other facing out of the active site.
Presently, the oxidized Cys-215 remains active. VO(acac)2 forms Electrostatic interactions with
active site Cys-215 which may block substrate biding in the active site and/or decrease catalytic
activity.
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Figure 4. Electrostatic interactions between the VO(acac)2 inhibitor and the PTP1B active site.
The hydrogen bonds between inhibitor and PTP1B are indicated by dashed lines. The crystal
structure of the PTP1B: VO(acac)2 complex confirmed these noncovalent interactions.
Electrostatic interactions between the VO(acac)2 bound Cys-215 and the PTP1B active site
loop are shown (Figure 36). In the PTP1B covalent modification vanadium oxide (CVO)
formation, the oxygen atoms in the modified Cys-215 forms two hydrogen bonds with the side
chain hydroxyl of Ser-222 and the backbone amide of Arg-221; one of the oxygen atoms of
vanadate forms hydrogen bonds with the backbone amides of Gly-220, Ile-219 and Gly-218. The
second oxygen atom of vanadate is stabilized by the backbone amide groups of Arg-221 and a
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water molecule, which interacts with the third oxygen atom of vanadate. The fourth oxygen atom
forms hydrogen bonds with the backbone amide of Ser-216. In the sulfenic acid formation, the
oxygen atom in the modified Cys-215 forms one hydrogen bond with the backbone amide of
Ser-216.
Previous work by Robin Carr & Harren Jhoti[110] found in the oxidized PTP1B active site,
the sulphur atom in the Cys-215 has formed a covalent bond with the backbone amide of Ser-216.
A crystallographic soaking experiment of PTP1B with one identified inhibitor (2-phenylisoxazolidine-3, 5-dione) formed a sulphenyl-amide derivative of Cys-215. The sulphur Sγ atom
of Cys-215 formed a covalent bond between the backbone nitrogen atom of Ser-216[110] (Figure
37, B). The oxidation of catalytic Cys-215 formed sulphenyl-amide formation, which is a
protective intermediate in the oxidative inhibition of PTP1B and caused significant changes in
the enzyme active site.
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Figure 5. Superimposed images of sulphenyl-amide PTP1B (PDB: 1OES) (purple, A) and
VO(acac)2 inhibition of PTP1B (green, B) show structural changes in the catalytic Cys-215
active site. With VO(acac)2 inhibitor bound, the Sy atom of Cys-215 flips away from the
backbone nitrogen atom of Ser-216 and can no longer form a sulphenyl-amide bond.
In the previous research, after the oxidation of Cys-215 to sulphenic acid, the nitrogen atom
of Ser-216 on the backbone nucleophilic attacked the Sγ atom of Cys-215 and formed a 1.7 Å
covalent bond[110]. However, in the vanadate bound Cys-215 crystal structure of PTP1B sulfenylamide formation, the distance between the Sγ atom of Cys-215 and the nitrogen atom of Ser-216
was 2.9 Å, which suggested hydrogen bond formed (Figure 37, A). The present structure
identifies an intermediate of their proposed mechanism of inactivation. This study provides
insight to further understanding of the redox inactivation of such proteins.
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Figure 6. Superimposition of the oxidation state structures of the PTP1B catalytic cysteine. The
structure of the sulphenic acid derivative of Cys-215 is shown in blue (A). The structure of the
VO(acac)2 derivative is in green (B). The phosphate binding cradle structure is largely conserved
with VO(acac)2 bound to the catalytic cystine.
The structures of key residues at the active site of the VO(acac)2 derivative are very similar
to the structure of the sulphenyl-amide derivative oxidation states (Figure 38). And the structures
of these oxidation states are very similar to the structure of reduced PTP1B. The vanadate bound
Cys-215 intermediate is stabilized by the similar interactions observed for the oxygen atoms in
the sulphenic acid derivate. However, in the sulfenic acid derivative, the side chain of A Cys-215
is rotated about 180o.
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The movement of the WPD-loop (a conserved protein loop) is important in the PTP1B
catalyzed reaction. The WPD-loop has a “closed” and an “open” two distinct conformation. The
WPD-loop would fold over the active site and bring the conserved Asp residue up to 8 Å closer
to the bound substrate. The WPD-loop has negligible interaction with the P-loop in the “open”
conformations[114-117]. The Vanadate also may reduce the mobility of the WPD-loop, which may
decrease catalytic activity.

Figure 7. Overlay of the WPD-loop open vanadate-bound (green) and the WPD-loop closed
conformations in the active sites of the PTP1B enzymes. The trigonal bipyramidal structure of
the vanadate anion is formed by a nucleophilic attack on the catalytic cystine. This also results in
a conformational change in the F182 residue.
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Different from Johnson’s result[112], in the crystal grown in the presence of vanadate, a
WPD-loop open vanadate-bound form conformation is observed. The conformational differences
between the open and closed conformations in the WPD-loop and the side chain of Arg-221of
the PTP1B in both the ligand-bound and ligand-free states had been shown (Figure 39).
In the WPD-loop open vanadate-bound form (Figure 39, B), the bound vanadate exhibits a
trigonal bipyramidal conformation with apical positions occupied by the sulfur atom of Cys-215
and an oxygen atom from a water molecule. Compared with the WPD-loop closed form (Figure
39, A), the side chain of Arg-221 is rotated about 70o around chi-3 and form a hydrogen bond to
the Phe-179 carbonyl group. In both the open and closed forms, the side chain of Phe-179 is
embedded into a hydrophobic pocket. Unlike the WPD-loop, the P-loop has no significant
motion during catalysis[118]. The P-loop backbone residues align closely in both the ligand-bound
and ligand-free states.
Kinetic results of PTP1B with VO(acac)2 Complex
The data obtained using VO(acac)2 complex as an inhibitor is shown in Figure 40. The
kinetic data suggests a competitive mode of inhibition because the apparent Vmax decreases,
while the apparent Km decreases, too. The concentration of vanadium complex varied from 00.3333 uM. The initial kinetic parameters obtained without vanadium complex are Vmax= 0.007
U/mM and Km= 2.8±0.1mM. After 16 hours, the PTP1B lost 2/3 activities compared with the
new purified protein (Figure 41).
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Figure 8. Activity versus substrate concentration for PTP1B against pNPP2- in the presence of
varying VO(acac)2 complex concentrations.
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Figure 9. Activity versus time for PTP1B.
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Materials and Methods
Materials
Chemicals for PTP1B purification, crystallization, assays were purchased from SigmaAldrich (St. Louis, MO), Alfa Aesar (Tewksbury, MA) and Fisher Scientific (Pittsburgh, PA).
YczR gene was synthesized with codon optimization for E. coli expression from Integrated DNA
Technologies (Coralville, IA). E. coli BL21 (DE3) cells and Turbo cells were purchased from
New England BioLabs (Ipswich, MA). Bacterial growth media Luria-Bertani (LB) broth and
antibiotics were obtained from Sigma-Aldrich. Crystallization screen solutions and other
crystallization supplies were purchased from Hampton Research (Aliso Viejo, CA) and Emerald
Bio (Bedford, MA). All other materials were purchased at the highest quality available.
Methods
DNA Cloning. The PTP1B DNA fragment was digested with NdeI and NotI and
subsequently cloned into the expression vector pETite. Transform the pETite-kan-c-5His vector
with full-length PTP1B insert into E. coli Turbo cells for plasmid storage. The PTP1B plasmid
was determined that there were no mutations in the entire coding region by DNA sequencing.
(DNA sequencing & Genotyping Facility, University of Chicago, Chicago, IL) The resulting
plasmid PTP1B was transferred to competent E. coli BL21DE3 cells for protein production and
purification.
Protein expression and purification. The PTP1B protein was purified by using the inteinmediated purification with an affinity His-tag system. E. coli BL21DE3 cultures were grown
overnight at 37°C while being shaken (250 RPM) in LB medium containing kanamycin (50
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ug/mL). Induction of PTP1B expression was carried out at an OD600 reached 0.6-0.8 by adding
IPTG to a final concentration of 0.5 mM. Cells were harvested after 16 h incubation by
centrifugation at 8670 G and 4 °C for 15 min (Avanti J-E Centrifuge, Beckman Coulter).
The cell pellet was resuspended in Ni-NTA column wash buffer (what is Ni column
buffer). Using sonication (Qsonica sonicators, Q500 Sonicator) to break the cellular wall, the cell
debris was removed by centrifugation at 31000G and 4°C for 20 min.
Protein purification was purified using affinity chromatography (Ni-NTA, GE Healthcare).
The Ni-NTA column was equilibrated with a wash buffer (50 mM NaH2PO4, 500 mM NaCl,
and 10 mM imidazole, pH 7.5) and the PTP1B fusion protein was eluted from the column using
wash buffer with imidazole (100 mM)
The fractions protein was concentrated to 2 mL using a 10 kDa Amicon-Ultra centrifuge
filter tube (Centricon Plus centrifugal filter units; Millipore). Further purified by size-exclusion
chromatography (HiLoad 16/60 Superdex 200, GE Healthcare), which was equilibrated with gel
filtration column buffer (300 mM NaCl, 50mM HEPES, pH 7.5).
The protein concentration was determined with a Bio-Rad protein assay kit. The protein
purity assessed by SDS-PAGE. Purified PTP1B protein was concentrated (Centricon Plus
centrifugal filter units; Millipore) and flash frozen in 1000µL aliquots in liquid nitrogen after the
addition of 20% (V/V) glycerol and stored at -80°C for long-term.
Synthesis Specific compounds as potential PTP1B inhibitors. VO(acac)2 had been
synthesized from vanadyl sulfate: VOSO4 + 2 Hacac → VO(acac)2 + H2SO4. The procedures
were slightly modified from the reported in the literature[112]. Syntheses VO(acac)2 complexes
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was performed under a pure N2 atmosphere using standard Schlenk and air-free manipulation
techniques. The vanadium forms a square pyramidal structure. After the reaction, the complexes
are purified using recrystallization.
Crystallization. The purified YczR was buffer exchanged into crystallization screening
buffer (50 mM HEPES, pH 7.5, 300 nM NaCl) and concentrated to 10 mg/ mL using a 10,0000
molecular weight cutoff (MWCO) Amicon-Ultra centrifugal filter device (Millipore). PTP1B
and VO(acac)2 were pre-mixed before crystallization. The initial sparse matrix crystal screen was
using the Gryphon crystallization robot (Art Robbins Instruments) to obtain initial crystallization
hits, and further optimized manually to obtain crystals with the best size and morphology.
After the initial crystallization screen, crystal optimizations of PTP1B were obtained by the
hanging drop method using protein at 10 mg/mL at room temperature. The optimized
crystallization solution contained 20% (W/V) PEG6000, 100 mM HEPES, pH 7.5, 200 mM
MgCl2. The hanging drops were incubated at room temperature. Crystals appeared in 6 days and
grew to maximum size in1-2 week.
Crystals with good size and morphology were picked from the hanging drops and flashcooled in liquid nitrogen using 20% (w/v) glycerol in addition to the compounds of the reservoir
solution as the cryoprotectant.
Diffraction data collection, Structure Determination, and Refinement. Diffraction data
of PTP1B crystals were collected at Advanced Photon Source Structural Biology Center (SBC)
19ID and 19BM beamlines. (Argonne National Laboratory, IL). The crystal diffraction images
were recorded by the 4×4 tiled 300×300 mm2 sensitive area CCD detector from Area Detector
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Systems Corp. (ADSC). The data collection was at a wavelength of 1.0 Å. The datasets were
indexed, integrated and scaled using the HKL2000[74]. The datasets were all scaled in the space
group P21 to resolutions of 2.2 Å respectively.
Using PHASER[75] from CCP4 program suite performed molecular replacement, using the
previously reported PTP1B (PDB ID: 1BZJ) as the search model[117]. Rigid body refinement
followed by restrained refinement was carried out in Refmac5 in the CCP4 software suits until
no more side chains can be built in automatically[78].
The remainder of the model was built and modified manually in Coot based on electron
density maps. Before built the ligand in the model, the electron density from the Fo-Fc map
supported the existence of the modification of Cys-215. The chemical restraint of Vanadium
compound was generated in the program JLigand from CCP4.
The ligand was manually fit in the model based the residual electron density in the
deference (Fo-Fc) map. The PTP1B with Vanadium ligand model was further refined in Refmac
5. The R free and R factor for the inactivated structure were 0.226 and 0.177, respectively. The
data collection and refinement statistics for the PTP1B are given in Table 2. All figures depicting
crystal structures were prepared by using Chimera.
PTP1B inhibition assay. The PTP1B assay was used Synergy H1 hybrid multimode
microplate reader (Biotek, USA) with 96 well plates (Greiner Bio-one, Monroe, NC). The
PTP1B assay was carried out in a continuous manner using para-nitrophenylphosphate (pNPP2-)
as the substrate. The absorbance of the product para-nitrophenol (pNP) was measured at 405 nm
using a microplate reader. All inhibitors were pre-incubated with PTP1B in a buffer containing
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50 mM HEPES (pH7.5), and 5 mM DTT, 300 mM NaCl for 5 min at 25 °C. The reaction that
was followed is given in equation.
pNPP2-(aq) + H2O(aq) à PO43- (aq) + pNP (aq) +H+ (aq)
Calculate enzyme activity from the data. The assay was carried out at 25 °C using the
substrate pNPP2- in the presence of 2 mM EDTA in a 50 mM Bis-Tris (pH 6.3) buffer, which
provides a constant ionic strength over a wide pH range.
Reactions were initiated by addition of enzyme into the microplate wells (final reaction
volume of 300 uL). Inhibition constants (Ki) for PTP1B were determined by measuring initial
rates of pNPP hydrolysis in the presence of a range of concentrations of inhibitor (0-3.33 uM)
and [pNPP2-] (0-20 mM) at pH 6.3 and 25 °C. Kinetic parameters were determined by a fit of the
initial rate (v) versus [pNPP2-] data to the Michaelis-Menten equation.

CHAPTER SEVEN
CONCLUSIONS
PTP1B is one of the most studied PTPs and plays a critical role in the regulation of the
insulin-signaling pathway[84, 114]. The highly charged PTP1B catalytic site contains the common
structural motif of PTPs. In the research pertaining to inhibition of PTP1B, specificity issues
with other PTPs still present significant challenges, because of the high homogeneity to other
cellular PTPs. It also remains a challenge in medicinal chemistry to design inhibitors with
relatively uncharged outer surfaces and hydrophobic regions. This design would allow the
inhibitor to cross membranes while maintaining relative efficacy once inside cells.
PTPs specifically catalyze the dephosphorylation of phosphotyrosyl residues of peptides
and proteins[119-121]. Orthovanadate (VO43-) is a phosphate analog that can quickly adopt a
trigonal bipyramidal structure and could bind as a transition state analog to inhibit the PTP1B[122].
Previous research has proved this part of vanadate’s insulin-mimetic effect due to its PTPs
inhibition function[123].
Vanadate was reported to inhibit protein phosphotyrosine phosphatase and activate
autophospohrylation of solubilized insulin receptors[124]. Vanadate is insulin-mimetic[125] , and its
insulin-mimetic properties have been researched in details[107]. It has been shown to be
potentially useful in treating both noninsulin- and insulin-dependent diabetes mellitus in human
clinical trials[126]. Vanadate has multitudinous effects on biological systems[123]. The
biochemistry of vanadate behaves like phosphate due to their similar molecular geometry [127].
89
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Vanadate may also have a strong affinity for the PTP1B active site[119-121, 128].
Vanadate would chelate many organic molecules and also reversibly coordinate free thiol
and hydroxyl groups. The interaction of vanadate with assay components and buffers has also
been monitored in research investigating the mechanism of vanadate inhibition [106]. HEPES was
chosen for the studies because it is one of the few buffers that does not have appreciable
interaction with vanadate[106].
After VO(acac)2 enters the cell, it would be degraded to vanadyl (IV) ion, and got oxdiated
to vanadate (V)[129-131]. Furthermore, vanadate often was treated as a simple phosphate analog. Its
rich redox and coordination chemistry also need to be considered, including coordination with
many reagents and varied oxidation states[107].
Here we report the X-ray structure of PTP1B with VO(acac)2 complex at a 2.2Å resolution.
The detailed PTP1B crystal structure may provide more information about the ability of
VO(acac)2 to bind the active site and inhibit PTP1B activity. The results suggest that the
oxovanadium (IV) complex VO(acac)2 dissociates and oxidizes to a vanadium (V) species
vanadate (VO43-) under crystallization conditions. This structure further suggests that better
bioavailability of VO(acac)2 is the primary reason for its enhanced inhibitory behavior compared
to simple salts[132].
While the precise biochemical pathway of vanadate action is not yet known, these kinetics
assay and X-ray crystallography studies will provide reliable proof of concept, validating the
inhibition of PTP1B by VO(acac)2. Catalytic cysteine exists as a thiolate anion, making it
susceptible to oxidation and more reactive. The mechanism of decrease regulating PTP1B
activity in vivo may occur because of the oxidation of the catalytic Cys-215 in the active site.
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Dithiothreitol (DTT) or glutathione can reduce the disulphides with Cys-215 to resore PTP1B
activity .
[111]

An essential cysteine residue at the catalytic site is the hallmark of PTPs. The cysteine
would form a Thiol-phosphate intermediate during catalysis[133]. In this study, we set out to
elucidate the mechanisms of vanadate inhibition of PTP1B.
Compared with vanadium compounds, zinc compounds have received less attention in antidiabetic drug research. Zinc compounds also play essential structural roles in PTPs inhibition in
vivo[134]. Previous research has shown that zinc compounds do not show inhibition of PTP1B at
concentration lower than 10 uM[109].
Compared with previous research, this crystal structure also redefines the oxidation state of
the catalytic Cys-215 in PTP1B. The nucleophilic Sg atom of Cys-215 attacks the backbone
nitrogen atom of Ser-216 formed the sulphenyl-amide bond occurs through oxidation of Cys-215
to sulphenic acid. The hydrogen bond interaction between the Nd1 atom of the invariant His-214
side chain and the carbonyl oxygen atom of Cys-215 increases the partial charge on the
backbone nitrogen atom of Ser-216 and enhance its reactivity. This assumption supports the
nucleophilic substitution mechanism[114].
During the in vitro oxidation reactions of the cysteine and thiol residues, sulfenic acids are
commonly generated as intermediates[135]. We used a small organic vanadate molecule as a
useful model to research the redox-sensing assembly of the PTP1B active site functional groups.
The possible interactions and reactions of vanadate must be taken into consideration when these
inhibitors are used in vivo and in vitro. Our results may help to better understand the mechanism
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of inhibition of PTP1B, This would then aid in the design of potential inhibitors against the
crucial therapeutic target of diabetes treating.
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